FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. (12th June 2019)

• Record Type: Journal Article
• Authors: Fischer, K.; Porro Lurà, M.; Al‐Sawaf, O.; Bahlo, J.; Fink, A.; Tandon, M.; Dixon, M.; Robrecht, S.; Warburton, S.; Humphrey, K.; Samoylova, O.; Liberati, A.M.; Pinilla‐Ibarz, J.; Opat, S.; Sivcheva, L.; Le Dû, K.; Fogliatto, L.M.; Utoft Niemann, C.; Weinkove, R.; Robinson, S.; Kipps, T.J.; Boettcher, S.; Tausch, E.; Schary, W.L.; Eichhorst, B.; Wendtner, C.; Langerak, A.W.; Kreuzer, K.; Goede, V.; Stilgenbauer, S.; Mobasher, M.; Ritgen, M.; Hallek, M.;
• Is Part Of: Hematological oncology. Volume 37(2019)Supplement 2
• Page Start: 82
• Page End: 84
• Publication Date: 2019-06-12
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.52_2629
• Languages: English
• ISSNs: 0278-0232